PCLO.V - PharmaCielo Ltd.

TSXV - TSXV Delayed Price. Currency in CAD
3.2500
-0.1700 (-4.97%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close3.4200
Open3.4200
Bid3.2400 x 0
Ask3.2900 x 0
Day's Range3.2100 - 3.4300
52 Week Range2.5100 - 11.5000
Volume165,130
Avg. Volume130,469
Market Cap312.915M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4210
Earnings DateNov 25, 2019 - Dec 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.36
  • PharmaCielo Announces RSU Grant
    CNW Group

    PharmaCielo Announces RSU Grant

    PharmaCielo Announces RSU Grant

  • CNW Group

    IIROC Trading Resumption - PCLO

    IIROC Trading Resumption - PCLO

  • PharmaCielo Announces Termination of Scheme Implementation Agreement with Creso Pharma
    CNW Group

    PharmaCielo Announces Termination of Scheme Implementation Agreement with Creso Pharma

    TORONTO , Nov. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF) announces that earlier today it was advised by Creso Pharma Limited ("Creso Pharma") that due to BDO Corporate Finance (WA) Pty Ltd. changing its independent expert report to conclude that the PharmaCielo Share Scheme is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma, it is impossible for the Board of Directors of Creso Pharma to support the Share and Option Schemes (the "Schemes") in their current form. As a result of the Creso Pharma Board of Directors changing its recommendation in respect of the Schemes, PharmaCielo has terminated the Scheme Implementation Agreement (the "Scheme Implementation Agreement"), originally announced on June 6, 2019 , in accordance with its terms.

  • CNW Group

    PharmaCielo Trading Halted Pending Update from Creso Pharma

    TORONTO , Nov. 4, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that trading in its common shares was halted today, pending an update from Creso Pharma Limited ("Creso Pharma") in respect of PharmaCielo's proposed acquisition of the company, which was originally announced on June 6, 2019 . As outlined in a press release on November 1, 2019 , BDO Corporate Finance (WA) Pty Ltd. has updated its independent expert report dated September 26, 2019 , to conclude that the Share Scheme of Arrangement (the "Share Scheme") under which PharmaCielo has proposed to acquire all of the issued and outstanding shares of Creso Pharma, is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma.

  • CNW Group

    IIROC Trading Halt - PCLO

    IIROC Trading Halt - PCLO

  • PharmaCielo Provides Update on Proposed Acquisition of Creso Pharma
    CNW Group

    PharmaCielo Provides Update on Proposed Acquisition of Creso Pharma

    TORONTO , Nov. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that in respect of its proposed acquisition of Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019 , and prior to the opening of the markets this morning, the Company was advised that Creso Pharma had received a supplementary independent expert report from BDO Corporate Finance (WA) Pty Ltd. updating its September 26, 2019 report, to now conclude that the Share Scheme of Arrangement (the "Share Scheme") under which PharmaCielo has proposed to acquire all of the issued and outstanding shares of Creso Pharma, is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma. The PharmaCielo Board of Directors has communicated that while it remains committed to closing the proposed transaction with Creso Pharma in its current form and in a disciplined manner, it will not increase the consideration that has been offered to Creso Pharma shareholders and listed optionholders as part of the acquisition.

  • PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders
    CNW Group

    PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders

    PharmaCielo's acquisition of Creso Pharma will establish a global medicinal cannabis company, positioned to rapidly develop new markets and grow sales in the expanded footprint served by the combined company. TORONTO , Oct. 2, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), is pleased to announce key developments in respect of its friendly acquisition of Australian Securities Exchange ("ASX") listed Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019 . Creso Pharma has informed the Company that it has received approval from the Supreme Court of Western Australia (the "Court") to convene meetings of its shareholders and listed optionholders (the "Meetings"), and if thought fit, to approve the Schemes of Arrangement whereby PharmaCielo would acquire all of the issued and outstanding shares and listed options of Creso Pharma (the "Schemes of Arrangement").

  • Horizons ETFs Rebalances Marijuana-Focused Index ETF Suite
    CNW Group

    Horizons ETFs Rebalances Marijuana-Focused Index ETF Suite

    Horizons ETFs Rebalances Marijuana-Focused Index ETF Suite

  • PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC
    CNW Group

    PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC

    PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC

  • PharmaCielo Announces Financial Results for the Second Quarter 2019
    CNW Group

    PharmaCielo Announces Financial Results for the Second Quarter 2019

    PharmaCielo Announces Financial Results for the Second Quarter 2019

  • PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe
    CNW Group

    PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe

    TORONTO and CHAM, Switzerland , Aug. 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., confirmed today it successfully completed the first commercial export of CBD isolate to Europe . The inaugural shipment of the high quality CBD isolate, a key ingredient in various cannabis derived therapeutic, nutraceutical, topicals and lifestyle products, was delivered to the Swiss headquarters of Creso Pharma, a global pharmaceutical with expertise in cannabis- and hemp-derived products for human and veterinarian use. This comes on the heels of the Colombian government granting the first commercial CBD isolate exporting permit to PharmaCielo, as announced on July 25, 2019 .

  • PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler
    CNW Group

    PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler

    TORONTO and MONTEVIDEO, Uruguay , Aug. 13, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced it has signed a sales agreement with Uruguay -based Laboratorios Adler ("Adler"). According to the agreement, PharmaCielo will provide Adler with bulk CBD extracts, bulk and bottled CBD oils and veterinary products that will be sold by Adler in Uruguay , Paraguay , Bolivia and Southern Brazil .

  • PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative
    CNW Group

    PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative

    TORONTO and RIONEGRO, Colombia , Aug. 8, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced it has joined the TruTrace Technologies, Inc. ("TruTrace") (CSE:TTT, OTCQB:TTTSF) and Shoppers Drug Mart initiated medical cannabis pilot verification program ("Pilot Program").

  • PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors

    PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors

  • PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts
    CNW Group

    PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts

    TORONTO and RIONEGRO, Colombia , Aug. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is ramping up its oil processing capabilities in the Company's Rionegro, Colombia facility following the recent acquisition and installation of additional high-performance, high-volume extractors, combined with proprietary extraction techniques.

  • Benzinga

    The Cannabis Sustainability Inquiry: Could Marijuana And Hemp Offer The Solution To The World's Toughest Environmental, Social, And Economic Problems?

    As a nascent (legal) consumer industry, the cannabis industry has a chance to invent itself from the ground up in the image of modern-day social, economic, and environmental sustainability. In March 2020 the United Nations is set to vote on what may be the termination of a half-Century of Treaty ban on Cannabis medicines. The World Health Organization is actively in the process of unprecedented scientific assessment of Cannabis, cannabinoids and Cannabis derivatives to begin to separate global stigma of the plant from the potential, its truly untapped medicinal, health-oriented public benefits.

  • Market Exclusive

    PharmaCielo to Begin Export of CBD Extracts from Colombia

    PharmaCielo Ltd. (TSXV: PCLO) (OTC: PHCEF), the Canadian parent of Colombia's cultivator and producer of medicinal-grade cannabis extracts PharmaCielo Colombia Holdings S.A.S., announced that it has completed the necessary permitting process required to enable Colombia's first commercial export and sale of non-psychoactive (CBD) isolate. The process fulfills the extensive and final regulatory obligations required, including […]The post PharmaCielo to Begin Export of CBD Extracts from Colombia appeared first on Market Exclusive.

  • Market Exclusive

    Cannabis Stock News Daily Roundup July 29

    iAnthus Capital Holdings (CSE: IAN) (OTCQX: ITHUF) has reported several recent milestones in Massachusetts. The company’s Mayflower Medicinals was approved for a retail marijuana license by the City of Worcester License Commission to operate an adult-use dispensary. The company's medical marijuana cultivation and processing facility in Holliston is supplying flower, pre-rolls, distillate, and edibles to Mayflower’s […]The post Cannabis Stock News Daily Roundup July 29 appeared first on Market Exclusive.

  • PharmaCielo Completes Acquisition of Ubiquo Telemedicina
    CNW Group

    PharmaCielo Completes Acquisition of Ubiquo Telemedicina

    TORONTO , July 26, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has completed the acquisition of all of the shares (the "Acquisition") of Ubiquo Telemedicina S.A.S. ("Ubiquo Telemedicina"), previously announced on April 20, 2018 .

  • PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate
    CNW Group

    PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

    PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

  • PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer

    RIONEGRO, Colombia , July 22, 2019 /CNW/ - PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Colombia" or the "Company"), the premier cultivator and producer of medicinal-grade cannabis oils and extracts in Colombia and subsidiary of Canadian firm PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF), is pleased to announce the appointment of Andres Felipe Botero as Chief Operations Officer (COO).

  • PharmaCielo Ltd. (CVE:PCLO): When Will It Breakeven?
    Simply Wall St.

    PharmaCielo Ltd. (CVE:PCLO): When Will It Breakeven?

    PharmaCielo Ltd.'s (CVE:PCLO): PharmaCielo Ltd., through its subsidiary, PharmaCielo Colombia Holdings S.A.S...

  • GlobeNewswire

    Blueberries Medical Makes Significant Advances Towards Commercial Production & Provides Operational and Corporate Update

    Expansion of Cultivation Facilities: Newly constructed open-air greenhouses completed and fully operational, increasing initial production capacity by approximately 40% to 150,000 sq.ft. Upgrade to facility infrastructure, including irrigation and electrical systems, water reservoirs and propagation facility also completed. Extraction: Customized extraction line with capacity to process up to 75,000 kg/year of dried flower currently undergoing specializations and customization to meet EU-GMP standards. Strategic Partnerships: Announced several strategic partnerships including (i) an agreement with SLANG Worldwide (CSE:SLNG) (“Slang”) announced on July 11, 2019 to license their extensive portfolio of CPG (Consumer Packaged Goods) products and leverage Slang’s industry leading know-how and intellectual property to process and formulate cannabis products in Colombia and Argentina, (ii) a distribution agreement announced on February 14, 2019 with El Manantial, a local medical center network and (iii) a European distribution agreement announced on June 5, 2019.